February 29, 2024
GSK appoints Dr Jeannie Lee to the Board as non-executive director
GSK has appointed Dr Jeannie Lee to the Board of the Company as a Non-Executive Director, who will join the Board on 4 March 2024.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
February 28, 2024
Launch of PulseSight Therapeutics: advancing non-viral gene therapy for eye diseases
PulseSight Therapeutics SAS, a biotech company, launches with funding from Pureos Bioventures and ND Capital. It aims to validate its innovative delivery platform by advancing drugs for age-related macular diseases.
February 27, 2024
Akeada, Biological E. Limited in partnership to hasten access to dengue vaccine
A strategic partnership between Akeada and Biological E. Limited aims to hasten access to QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs) for National Immunization Programs by 2030. MDVs offer cost and logistical benefits, with BE aiming for a manufacturing capacity of 50 million doses yearly to support Takeda’s goal of 100 million doses annually within the decade.
January 12, 2024
UK Approval for AGAMREE in Duchenne muscular dystrophy treatment
Santhera Pharmaceuticals has revealed that AGAMREE (vamorolone) has received approval in the United Kingdom (UK) for treating Duchenne muscular dystrophy (DMD) in patients aged 4 and above, regardless of the underlying mutation and ambulatory status.
January 11, 2024
Mainz Biomed N.V. strengthens partnership with TestDNA to advance colorectal cancer detection in Poland
Mainz Biomed N.V., a company focused on molecular genetics diagnostics for early cancer detection, is confirming its collaboration with TestDNA at the forthcoming 10th Gdańsk Gastroenterology Symposium scheduled for January 12th–13th, 2024. The joint effort aims to progress the detection of colorectal cancer (CRC) in Poland, with a focus on introducing innovative approaches that can improve treatment choices and elevate survival rates through early identification of the disease.
January 8, 2024
Novartis’ Scemblix® shows promise in pivotal phase III trial for newly diagnosed CML patients
Novartis has reported successful outcomes for Scemblix® (asciminib) in its pivotal Phase III ASCFIRST trial, a head-to-head comparison for newly diagnosed patients with Philadelphia chromosome-positive CML (Ph+ CML-CP).
January 4, 2024
Destiny Pharma Advances Strategic Plans with Focus on XF-73 Nasal and NTCD-M3 Programs
Destiny Pharma, a clinical-stage biotech firm dedicated to developing and marketing innovative medicines to prevent life-threatening infections, has issued a year-end business update, as it focuses on XF-73 nasal and NTCD-M3 programs.
January 2, 2024
£6.3m HRV contract signed with biotechnology client
hVIVO has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV – common cold virus) Human Challenge Study Model.
January 2, 2024
Roche to buy Point of Care Diagnostics Companies for $295 million
Roche is to acquire all of the Point of Care Diagnostics Companies for the sum of $295 million, subject to customary closing adjustments
December 29, 2023
I want to become a Cyborg, do you? Also, hear the words for the last weekend of the 2023
The society is changing rapidly, millennials are now 40 years old people, and it’s OK. The Gen-X folks are already planning retirement days, and the world is left into the hands of – I don’t even know what do we call our children – but they’re children. It looks scary to me. We are still here, and we will inform about pharmaceuticals.